Schrodinger, Inc. Reports 2025 Annual Results: Growth Amidst Challenges
Schrodinger, Inc., a prominent player in the biotechnology sector, has released its annual report for 2025, showcasing a mix of achievements and hurdles. The company is renowned for its physics-based computational platform that enhances the discovery of therapeutics and materials, particularly through its software solutions utilized by biopharmaceutical firms and academic institutions globally.
1. Financial Highlights
For the fiscal year ending December 31, 2025, Schrodinger reported total revenue of $255.9 million, representing a significant increase from $207.5 million in 2024. However, the company also faced a net loss of $103.3 million, a notable improvement from the $187.1 million loss reported the previous year.
Revenue Breakdown
The revenue growth was primarily driven by the drug discovery segment, which skyrocketed by 107.44% to $56.36 million, compared to $27.17 million in 2024. The software segment also contributed significantly, generating $199.5 million, reflecting a 10.61% increase.
Geographic Distribution of Revenue
The company's revenue by geography in 2025 highlighted the United States as the most significant contributor, accounting for $152.9 million (up 33.16% from 2024), followed by EMEA with $75.16 million (up 14.49%), APAC with $26.18 million (up 1.47%), and the Rest of the World with $1.56 million (up 28.16%).
2. Operating Expenses and Losses
Operating expenses totaled $422.7 million, with significant allocations toward research and development (R&D), which reached $173.1 million. The selling, general, and administrative expenses contributed another $136.3 million. The total non-operating income was $64.57 million, which helped offset some operational losses.
| Feb 2025 | Feb 2026 | |
|---|---|---|
Net Income | -187.1M | -103.2M |
Profit | -187.1M | -103.2M |
Net Income Continuing | -187.1M | -103.2M |
Income Tax Expense | 1.41M | 939K |
Pretax Income | -185.7M | -102.3M |
Non-operating Income | 23.58M | 64.57M |
Operating Income | -209.2M | -166.8M |
Revenue | 207.5M | 255.8M |
Costs and Expenses | 416.8M | 422.7M |
Cost of Revenue | 75.45M | 113.2M |
Operating Expenses | 341.3M | 309.5M |
Research & Development | 201.7M | 173.1M |
Selling, General & Administrative | 139.5M | 136.3M |
Restructuring Initiatives
In May 2025, Schrodinger initiated a restructuring plan expected to reduce annual operating expenses by approximately $30 million, accompanied by a workforce reduction of about 60 employees, or 7% of its total staff. This restructuring incurred a one-time charge of $3 million.
3. Clinical Trials and Drug Discovery Programs
The company’s proprietary drug discovery programs continue to progress, with the MALT1 inhibitor, SGR-1505, and the Wee1/Myt1 inhibitor, SGR-3515, both undergoing Phase 1 clinical trials. However, Schrodinger faced a setback with the discontinuation of the SGR-2921 clinical development program due to safety concerns.
Strategic Partnerships
Schrodinger maintains strategic collaborations with major biopharmaceutical companies, including Bristol-Myers Squibb and Eli Lilly, which could yield milestone payments totaling up to $902 million. A recent partnership with Novartis includes an upfront fee of $150 million and potential milestone payments of up to $2.272 billion.
4. Cash Flow and Liquidity
As of December 31, 2025, Schrodinger has a robust liquidity position with cash and equivalents totaling $402.3 million. This amount is expected to fund operational expenses and capital requirements for the next 24 months.
| Feb 2025 | Feb 2026 | |
|---|---|---|
Net Change in Cash | 1.59M | 74.72M |
Net Cash from Operating Activities | -157.3M | 13.89M |
Operating Profit | -187.1M | -103.2M |
Adjustment to Operating Profit | 29.75M | 117.1M |
Net Cash from Investing Activities | 148.8M | 57.89M |
Business & Interest in Affiliates | -45.72M | -17.73M |
Investments | -110.4M | -41.60M |
Productive Assets | 7.31M | 1.44M |
Net Cash from Financing Activities | 10.12M | 2.93M |
Debt | -58K | -58K |
Equity Issuance/Repurchase | 10.35M | 2.98M |
Other Financing Activities | -177K | 0 |
5. Balance Sheet Overview
The balance sheet reflects total assets of $726.1 million, with total liabilities at $362.1 million, resulting in total equity of $364.0 million. The company’s equity consists of common stock equity and additional paid-in capital, with retained earnings reflecting a deficit of $628.8 million.
| Feb 2025 | Feb 2026 | |
|---|---|---|
Total Assets | 823.2M | 726.1M |
Total Current Assets | 634.9M | 519.2M |
Cash and Equivalents | 147.3M | 230.5M |
Short-term Investments | 204.7M | 164.9M |
Accounts Receivable | 235.6M | 83.04M |
Restricted Cash and Investments | 15.33M | 6.86M |
Prepaid Expenses | 12.20M | 12.54M |
Other Current Assets | 19.64M | 21.35M |
Total Non-current Assets | 188.2M | 206.8M |
Intangible Assets | 4.79M | 4.79M |
Long-term Investments | 43.20M | 73.64M |
Net PP&E | 24.19M | 19.45M |
Lease Assets | 111.8M | 102.7M |
Other Non-current Assets | 4.15M | 6.26M |
Total Liabilities and Equity | 823.2M | 726.1M |
Total Liabilities | 401.7M | 362.1M |
Total Current Liabilities | 191.7M | 189.1M |
Accounts Payable and Accrued Liabilities | 63.04M | 59.87M |
Current Debt | 16.75M | 16.41M |
Current Deferred Revenue | 111.9M | 112.8M |
Total Non-current Liabilities | 210.0M | 172.9M |
Non-current Deferred Revenue | 108.8M | 78.87M |
Other Non-current Liabilities | 101.2M | 94.09M |
Total Equity and Non-controlling Interests | 421.4M | 364.0M |
Total Equity | 421.4M | 364.0M |
6. Conclusion
Schrodinger, Inc. is navigating a challenging yet promising landscape in drug discovery and software development. The company’s strategic restructuring efforts and strong collaborations position it well for future growth, even as it addresses operational losses and clinical trial challenges. With a focus on enhancing its computational platform and rigorous management of financial performance, Schrodinger looks to capitalize on its innovative capabilities in the evolving biotechnology sector.
